These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 15938857

  • 1. [Relationship between B virus hepatitis genotypes and therapeutic efficacy in early treatment for chronic hepatitis B by using lamivudine].
    Song SJ, Zhuang H, Yan J, Wei HS, He ZP, Song C, Dong QM, Xiao YP.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2005 May; 39(3):203-5. PubMed ID: 15938857
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R, Kumashiro R, Murashima S, Ogata K, Tanaka K, Hisamochi A, Hino T, Ide T, Tanaka E, Koga Y, Sata M.
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [Abstract] [Full Text] [Related]

  • 5. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF.
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [Abstract] [Full Text] [Related]

  • 6. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
    Sun J, Wang Z, Ma S, Zeng G, Zhou Z, Luo K, Hou J.
    J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M, Xu B, Yao GB.
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. YMDD mutations and genotypes of hepatitis B virus in northern China.
    Li D, Gu HX, Zhang SY, Zhong ZH, Zhuang M, Hattori T.
    Jpn J Infect Dis; 2006 Feb; 59(1):42-5. PubMed ID: 16495633
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH, Lu SN, Chen CH, Wang JH, Wu CM, Hung CH, Tseng PL, Hu TH, Changchien CS, Lee CM.
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [Abstract] [Full Text] [Related]

  • 16. [The relationship between HBV genotypes and the efficacy of antiviral therapies in hepatitis B e antigen- positive patients].
    Zou HB, Zhu LM, Zhao GM, Liang SR, Li J, Lu CZ, Li H.
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):425-7. PubMed ID: 17594806
    [Abstract] [Full Text] [Related]

  • 17. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN, Chauhan R, Das BC, Sarin SK.
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [Abstract] [Full Text] [Related]

  • 18. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL.
    Antivir Ther; 2007 Oct; 12(8):1295-303. PubMed ID: 18240869
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.